UK breast cancer diagnostics and therapeutics market are estimated to grow significantly at a CAGR of 9.0% during the forecast period. Increasing the incidence of breast cancer coupled with government intitives are the major factors that contributing to the growth of the market. According to Cancer Research UK, incidence rates for breast cancer are projected to rise by 2% in the UK between 2014 and 2035, to 210 cases per 100,000 females by 2035. The awareness programs and research funding on breast cancer also enable the growth of the market. In 2015 the Public Health England (PHE) launched the ‘Be Clear on Cancer’ campaign for the purpose of women aged 70 and over to drive awareness of the risk of breast cancer. Cancer Research UK funded about $38 million for breast cancer research in 2017. This funding enabled to create a network of research at 90 institutions in more than 40 states in the UK.
(Get 15% Discount on Buying this Report)
Get Report Sample Copy @ https://www.omrglobal.com/request-sample/uk-breast-cancer-diagnostics-therapeutics-market
UK breast cancer diagnosis and therapeutics market are segmented on the basis of cancer type, diagnostics, and therapeutics. In cancer type segment market is further classified into ductal carcinoma in-situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC), inflammatory breast cancer and others. In diagnostics technology, the segment market is further classified into mammography, biopsy, position emission tomography/computed tomography, ultrasound, and others. The therapeutics technology segment market is further segregated into chemotherapy, hormone therapy, targeted therapy, and others.
A Full Report of Global IoT Sensors Market is Available at: https://www.omrglobal.com/industry-reports/uk-breast-cancer-diagnostics-therapeutics-market
Market Segmentation
UK Breast Cancer Diagnostics and Therapeutics Market by Cancer Type
- Ductal Carcinoma In-Situ (DCIS)
- Invasive Ductal Carcinoma (IDC)
- Triple Negative Breast Cancer (TNBC)
- Inflammatory Breast Cancer
- Others (Invasive lobular carcinoma)
UK Breast Cancer Diagnostics and Therapeutics Market by Diagnostics
- Mammography
- Biopsy
- PET/CET
- Ultrasound
- Others (MRI)
UK Breast Cancer Diagnostics and Therapeutics Market by Therapeutics
- Chemotherapy
- Hormone Therapy
- Targeted Therapy
- Others (Radiation Therapy, Surgery)
Company Profiles
- Agendia NV
- AstraZeneca PLC
- Bayer AG
- GlaxoSmithKline PLC
- Mylan NV
- Merck & Co., Inc.
- Novartis International AG
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/uk-breast-cancer-diagnostics-therapeutics-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
